A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors
Antineoplastic Combined Chemotherapy Protocols
For patients with advanced solid tumors, the maximum-tolerated dose of this drug combination was pralatrexate 40 mg/m(2) and probenecid 140 mg/m(2). Vitamin B(12) and folate supplementation may allow for further dose escalation of pralatrexate and probenecid. This is a suitable question for a future study.